Showing results (21-30 of 67) with videos related to
Sort By:
Pageof 7
Depression Research and Treatment|August 25, 2012
Depression treatment with duloxetine and reduction of inability to workMichael Happich, Edith Schneider, Stefan Wilhelm, et al.Child and Adolescent Psychiatry and Mental Health|December 8, 2010
Differences between children and adolescents in treatment response to atomoxetine and the correlation between health-related quality of life and Attention Deficit/Hyperactivity Disorder core symptoms: Meta-analysis of five atomoxetine trialsPeter M Wehmeier, Alexander Schacht, Rodrigo Escobar, et al.Attention Deficit and Hyperactivity Disorders|January 25, 2012
Health-related quality of life in ADHD: a pooled analysis of gender differences in five atomoxetine trialsPeter M Wehmeier, Alexander Schacht, Rodrigo Escobar, et al.Schizophrenia Research|February 17, 2007
Correlation of physician and patient rated quality of life during antipsychotic treatment in outpatients with schizophreniaPeter M Wehmeier, Michael Kluge, Alexander Schacht, et al.Journal of Attention Disorders|April 15, 2009
Atomoxetine's effect on societal costs in SwedenKarl-Johan Myrén, Gunilla Thernlund, Asa Nylén, et al.Neuropsychiatric Disease and Treatment|November 16, 2013
Switching to olanzapine long-acting injection from either oral olanzapine or any other antipsychotic: comparative post hoc analysesAntonio Ciudad, Ernie Anand, Lovisa Berggren, et al.Attention Deficit and Hyperactivity Disorders|March 18, 2010
Self-esteem in adolescent patients with attention-deficit/hyperactivity disorder during open-label atomoxetine treatment: psychometric evaluation of the Rosenberg Self-Esteem Scale and clinical findingsRalf W Dittmann, Peter M Wehmeier, Alexander Schacht, et al.Journal of Medical Economics|March 7, 2012
Healthcare utilization among patients with depression before and after initiating duloxetine in the United KingdomNianwen Shi, Zhun Cao, Emily Durden, et al.Child and Adolescent Psychiatry and Mental Health|February 11, 2009
Morning and evening behavior in children and adolescents treated with atomoxetine once daily for attention-deficit/hyperactivity disorder (ADHD): findings from two 24-week, open-label studiesPeter M Wehmeier, Ralf W Dittmann, Alexander Schacht, et al.Journal of Psychiatric Research|January 28, 2014
Impact of patient selection and study characteristics on signal detection in placebo-controlled trials with antidepressantsMichele Mancini, Alan G Wade, Giulio Perugi, et al.Pageof 7